

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently Amended) A method of treating or preventing an inflammatory disease or disorder comprising administering to an animal in which such treatment or prevention is desired an antibody or fragment thereof that specifically binds and antagonizes a TNF-gamma-beta protein at least 95% identical to SEQ ID NO:20 in an amount effective to treat or prevent ~~the~~ an inflammatory disease or disorder,

wherein the inflammatory disease or disorder is selected from the group consisting of septic shock, sepsis, systemic inflammatory response syndrome, ischemia-reperfusion injury, endotoxin lethality, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, over production of cytokines, respiratory disorders, multiple sclerosis; ischemic brain injury, stroke, traumatic brain injury, neurodegenerative disorders, AIDS-related dementia, prion disease, encephalitis, atherosclerosis, myocarditis, cardiovascular disease, cardiopulmonary bypass complications, hepatitis, rheumatoid arthritis, gout, trauma, pancreatitis, sarcoidosis, dermatitis, psoriasis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosus, diabetes mellitus, and allogenic transplant rejection.

2. (Original) The method of claim 1 wherein the animal is human.

3. (Original) The method of claim 1 wherein the antibody or fragment thereof specifically binds a TNF-gamma-beta protein selected from the group consisting of:

- (a) a protein whose sequence consists of amino acid residues 1 to 251 of SEQ ID NO:20;
- (b) a protein whose sequence consists of amino acid residues 62 to 251 of SEQ ID NO:20;
- (c) a protein whose sequence consists of amino acid residues 72 to 251 of SEQ ID NO:20;

- (d) a protein whose sequence consists of amino acid residues 101 to 251 of SEQ ID NO: 20;
  - (e) a protein whose sequence consists of amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 203055;
  - (f) a protein whose sequence consists of amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 203055; and
  - g) a protein whose sequence consists of the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 203055.
4. (Original) The method of claim 3 wherein the antibody or fragment thereof is a monoclonal antibody.
5. (Original) The method of claim 3 wherein the antibody or fragment thereof is a human antibody.
6. (Original) The method of claim 3 wherein the antibody or fragment thereof is a humanized antibody.
7. (Original) The method of claim 3 wherein the inflammatory disease or disorder is inflammatory bowel disease.
8. (Original) The method of claim 3 wherein the inflammatory disease or disorder is encephalitis.
9. (Original) The method of claim 3 wherein the inflammatory disease or disorder is atherosclerosis.

10. (Original) The method of claim 3 wherein the inflammatory disease or disorder is psoriasis.

11. (Currently amended) A method of treating or preventing inflammation comprising administering to an animal in which such treatment or prevention is desired an antibody or fragment thereof that specifically binds and antagonizes a TNF-gamma-beta protein at least 95% identical to SEQ ID NO:20 in an amount effective to treat or prevent the an inflammation associated with tissue-specific inflammatory disorders,

wherein the tissue-specific inflammatory disorder is selected from the group consisting of adrenalitis, alveolitis, angiocholecystitis, appendicitis, balanitis, blepharitis, bronchitis, bursitis, carditis, cellulitis, cervicitis, cholecystitis, chorditis, cochitis, colitis, conjunctivitis, cystitis, dermatitis, diverticulitis, encephalitis, endocarditis, esophagitis, eustachitis, fibrositis, folliculitis, gastritis, gastroenteritis, gingivitis, glossitis, hepatosplenitis, keratitis, labyrinthitis, laryngitis, lymphangitis, mastitis, media otitis, meningitis, metritis, mucitis, myocarditis, myositis, myringitis, nephritis, neuritis, orchitis, osteochondritis, otitis, pericarditis, peritendonitis, peritonitis, pharyngitis, phlebitis, poliomyelitis, prostatitis, pulpitis, retinitis, rhinitis, salpingitis, scleritis, sclerochoroiditis, scrotitis, sinusitis, spondylitis, steatitis, stomatitis, synovitis, syringitis, tendonitis, tonsillitis, urethritis, and vaginitis

12. (Original) The method of claim 11 wherein the animal is a human.

13. (Original) The method of claim 11 wherein the antibody specifically binds a TNF-gamma-beta protein selected from the group consisting of:

(a) a protein whose sequence consists of amino acid residues 1 to 251 of SEQ ID NO:20;

(b) a protein whose sequence consists of amino acid residues 62 to 251 of SEQ ID NO:20;

(c) a protein whose sequence consists of amino acid residues 72 to 251 of SEQ ID NO:20;

(d) a protein whose sequence consists of amino acid residues 101 to 251 of SEQ ID NO:20;

(e) a protein whose sequence consists of the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit Number 203055;

(f) a protein whose sequence consists of the amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 203055; and

(g) a protein whose sequence consists of the amino acid sequence of the mature form of the polypeptide encoded by the cDNA contained in ATCC Deposit Number 203055.

14. (Original) The method of claim 13 wherein the antibody or fragment thereof is a monoclonal antibody.

15. (Original) The method of claim 13 wherein the antibody or fragment thereof is a human antibody.

16. (Original) The method of claim 13 wherein the antibody or fragment thereof is a humanized antibody.

17. (Currently amended) A method of treating or preventing an autoimmune disease or disorder comprising administering to an animal in which such treatment or prevention is desired an antibody or fragment thereof that specifically binds and antagonizes a TNF-gamma-beta protein at least 95% identical to SEQ ID NO:20 in an amount effective to treat or prevent ~~the~~ inflammation associated with arthritis, multiple sclerosis, Crohn's disease, or autoimmune encephalitis.

18-28. (Canceled).

29. (Withdrawn) A method of treating or preventing graft versus host disease (GVHD) comprising administering to an animal in which such treatment or prevention is desired an

antibody or fragment thereof that specifically binds TNF-gamma-beta protein in an amount effective to treat or prevent the GVHD.

30-34. (Canceled)

35. (Withdrawn)      A method of killing a cell of hematopoietic origin comprising contacting a TNF-gamma-beta protein with a cell of hematopoietic origin.

36-49. (Canceled)